Document is current

Article History

Received: 18 October 2024

Accepted: 4 June 2025

First Online: 26 August 2025

Declarations

:

: Regarding experiments realized on R6/2 mice and WT-littermates, all animal procedures and experiments were approved by the local ethical committee (Ethical Committee of IBPS, n° 05) and the French Ministry of National Education, Higher Education and Research (reference number APAFIS #12412–2017113010191653 v7) and were performed in accordance with the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health). The HD brains were donated after informed consent by the patients themselves during life and these donations were supported by the spouse and doctors of these patients. The Medical Ethical committee of the University Medical Centre Groningen, the Netherlands approved the brain donation procedure, as well as the donation form and patient information.

: I give my consent for the publication of the manuscript titled Astrocyte-neuron combined targeting for CYP46A1 gene therapy in Huntington’s disease in Acta Neuropathologica communications. All co-authors have approved the final version, and we agree to the submission and publication. I confirm that all necessary permissions and consents (including for images or personal data) have been obtained.

: The clinical application of gene therapy approach for CYP46A1 delivery in Huntington’s disease is protected by the published patent filed in Europe and the United States, PCT/EP2011/068033 and WO2012049314A1, respectively.